Cosciens Biopharma Inc (CSCI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 1,607 | 1,467 | 1,408 | 1,475 | 1,444 |
| Income taxes - deferred | 79 | -901 | 1,016 | -344 | 0 |
| Accounts receivable | N/A | 1,788 | -615 | -138 | 1,243 |
| Other Working Capital | -2,514 | 57 | -841 | -626 | 468 |
| Other Operating Activity | -13,740 | -5,143 | 3,922 | 2,386 | 338 |
| Operating Cash Flow | $-14,568 | $-2,731 | $4,890 | $2,753 | $3,492 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,161 | -739 | -251 | -552 | -485 |
| Net Acquisitions | 26,037 | N/A | N/A | N/A | N/A |
| Other Investing Activity | 207 | 0 | -35 | -68 | 106 |
| Investing Cash Flow | $25,083 | $-739 | $-286 | $-620 | $-380 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -421 | -279 | -220 | -262 | -362 |
| Other Financing Activity | -167 | 5 | 60 | 21 | 4 |
| Financing Cash Flow | $-588 | $-274 | $-160 | $-241 | $-358 |
| Exchange Rate Effect | -212 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 6,678 | 10,411 | 5,733 | 4,211 | 1,456 |
| End Cash Position | 16,393 | 6,666 | 10,176 | 6,103 | 4,210 |
| Net Cash Flow | $9,927 | $-3,744 | $4,443 | $1,892 | $2,754 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,568 | -2,731 | 4,890 | 2,753 | 3,492 |
| Capital Expenditure | -1,161 | -739 | -251 | -556 | -485 |
| Free Cash Flow | -15,729 | -3,470 | 4,639 | 2,197 | 3,007 |